89 results about "Osteopoikilosis" patented technology

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.

A method and system for detection and tracking of osteoporosis is disclosed. A method of characterizing an image of a target vertebra includes building a computer model from a set of sample images of pathological and non-pathological variations of vertebrae representing variations in shape of the vertebrae. The method also includes receiving an image of a target vertebra of a subject and automatically estimating contours of lateral outlines of the superior and the inferior cortical endplates of the image. The parameters of the model are varied to determine a set that represents a model shape that approximates the estimated contours of the outlines of the cortical endplates. The method includes automatically characterizing the target vertebra based on the set of model parameters that are determined and outputting on a display device the characterization of the target vertebra.

A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.

The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.

Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.

A medicine for treating various diseases such as women's climacteric syndrome, osteoporosis, mental depression, premature ovarian failure, premenstrual tension syndrome, hyperthyroidism, male and female infertility, hair loss and white hair, and is characterized in that it It is composed of fatty acids in the following weight percent range: hexadecanoic acid 8-32%, hexadecenoic acid 11-35%, octadecenoic acid 13-33%, octadecanoic acid 0.3-2.5%, octadecanoic acid Carbadienoic acid 11-33%, octadecatrienoic acid 3-15%. Compared with other drugs, the drug composition is simple, belongs to the target organ agonist, and has an independent reversible regulation function on the second messenger of the body. It is a medicine with high curative effect, safety and simplification.

A medicinal puerarin composition used for preparing the medicine to treat the cardiovascular and cerebrovascular diseases and osteoporosis is prepared from puerarin and solubilizing agent chosen from hydroxy propyl-beta-cyclodextrin, beta-cyclodextrin and hydroxyethyl-beta-cyclodextrin. It has high water-solubility.

The invention discloses an ultrasonic CT imaging method of bone broad-band attenuation (BUA) detected by non-diffraction ultrasound, which is characterized by the following: adopting non-diffraction ultrasonic field as launching field to pierce bone; obtaining BUA parameter through fitful mathematical and physical method; reconstructing BUA cut image of bone through CT imaging technique; selecting Bessel ultrasonic field or X-wave ultrasonic field as non-diffraction ultrasonic field; improving imaging distinguishability with low cost effectively.

The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.

The invention provides a compound preparation for preventing and treating the osteoporosis and a preparation method thereof. The compound preparation consists of herba epimedii, radix achyranthis bidentatae, calcium citrate, casein phosphopeptides and magnesium stearate. The preparation method comprises the following steps: preparing powder by extracting the materials of the herba epimedii and the radix achyranthis bidentatae, sieving the calcium citrate, the casein phosphopeptides and the magnesium stearate, blending, mixing, granulating, metering, filling into capsules and packaging. The compound preparation and the preparation method provided by the invention have the advantages that elaborate prescription is adopted on the basis of the traditional theory of traditional Chinese medicine and the modern pharmacological research, the herba epimedii and the radix achyranthis bidentatae have the effects of nourishing liver and kidney and strengthening the muscles and bones; and by combination of the casein phosphopeptides and the calcium citrate, the absorption and utilization of calcium can be better enhanced, the calcium content in bones can be improved and the density of the bones can be increased, so that the two effects of increasing the density of the bones and preventing and treating the osteoporosis are achieved. A product prepared by the compound preparation not only is safe in administration and has obvious preventing and treating effects and health-care effect, but also is low in industrial production cost and has a good prospect for market development and application.

A method is disclosed for analyzing keratinized tissue, particularly fingernails, of a subject to diagnose osteoporosis and bone fracture risk. A Raman spectrum of a sample of keratinized tissue is generated. Broad spectral background features of the spectrum are removed, preferably by using Fourier transform analysis. Peak heights of Raman features of interest, particularly the S—S bond of cystine, are measured. These peak height measurements are normalized using reference peak heights of Raman features that are invariant between normal and osteoporotic subjects, such as the CH2 bending peak.

The present invention relates to a dual energy X-ray apparatus and method for osteoporosis assessment and monitoring. The present invention takes a bone densitometry reading of a patient's wrist to assess osteoporosis and monitor bone loss condition by repeat measurements along with therapy. The bone densitometry system has an X-ray source, dual energy detectors, an arm-rest to place the patient's arm, a motion system to move the source-detector gantry along the patient's forearm, and a computer with a database to archive the wrist image, calculate the bone mineral density, maintain a history of patient information, and generate patient history reports.